Molecular Partners Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Molecular Partners ha un patrimonio netto totale di CHF138.8M e un debito totale di CHF0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente CHF154.2M e CHF15.4M.

Informazioni chiave

Rapporto debito/patrimonio netto

CHF 0

Debito

Indice di copertura degli interessi	n/a
Contanti	CHF 143.62m
Patrimonio netto	CHF 138.78m
Totale passività	CHF 15.43m
Totale attività	CHF 154.21m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Sep 10

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Apr 11

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Jan 09

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Sep 08

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Jun 23

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Aug 31

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

May 09

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Dec 26

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Jun 24

Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability

Mar 09

Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts

Feb 10

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Jan 21

How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?

Dec 17

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( CHF149.5M ) di MOLN superano le sue passività a breve termine ( CHF10.4M ).

Passività a lungo termine: Le attività a breve termine di MOLN ( CHF149.5M ) superano le sue passività a lungo termine ( CHF5.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: MOLN è esente da debiti.

Riduzione del debito: MOLN non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: MOLN ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: MOLN ha una liquidità sufficiente per 1.9 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 1.7 % ogni anno.

Molecular Partners Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Recent updates

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Third quarter 2024 earnings released: CHF0.49 loss per share (vs CHF0.35 loss in 3Q 2023)

New minor risk - Shareholder dilution

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn Rate

Consensus revenue estimates decrease by 62%, EPS upgraded

Second quarter 2024 earnings released: CHF0.46 loss per share (vs CHF0.49 loss in 2Q 2023)

Price target decreased by 9.7% to CHF9.35

Price target increased by 11% to CHF10.35

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

First quarter 2024 earnings released: CHF0.34 loss per share (vs CHF0.45 loss in 1Q 2023)

Insufficient new directors

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Consensus revenue estimates fall by 45%

We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation

Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022)

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Consensus revenue estimates fall by 29%

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

New major risk - Share price stability

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022)

Consensus revenue estimates decrease by 40%

Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation

Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022)

Molecular Partners AG Announces Executive Changes

Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023

Consensus revenue estimates fall by 12%

First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022)

Consensus revenue estimates decrease by 73%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia

Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML

Price target decreased to CHF12.87

High number of new directors

Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors

Third quarter 2022 earnings released: CHF0.41 loss per share (vs CHF0.38 loss in 3Q 2021)

Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Investor sentiment improved over the past week

Consensus forecasts updated

What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today

Second quarter 2022 earnings released: CHF0.14 loss per share (vs CHF0.56 loss in 2Q 2021)

Price target increased to CHF30.57

Molecular Partners AG, Annual General Meeting, Apr 04, 2023

Johnson Fistel Files A Class Action Complain Against Molecular Partners AG

Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2

Price target increased to CHF30.57

Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – Moln

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans

Price target decreased to CHF26.83

High number of new directors

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19

Price target increased to CHF27.58

Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Forecast to breakeven in 2022

Price target decreased to CHF25.00

Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients

Third quarter 2021 earnings released: CHF0.38 loss per share (vs CHF0.67 loss in 3Q 2020)